SEER Cancer Statistics Review 1975-2017 National Cancer Institute · 2020-04-10 · SEER Cancer Statistics Review 1975-2017 National Cancer Institute Note: Incidence and death rates

SEER Cancer Statistics Review 1975-2017 National Cancer Institute

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US StdPopulation (19 age groups - Census P25-1130).

a SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle,Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia,California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey,Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

b US Mortality Files, National Center for Health Statistics, Centers for Disease Control andPrevention.

c SEER 18 areas. Based on follow-up of patients into 2017. Expected survival rates arederived from life tables by socio-economic status, geography and race developed by theSEER program.

d Mesotheliomas of the Pleura are included in the separate group Mesothelioma for incidencebut are included in the Pleura grouping for mortality.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Incidencea US Mortalityb Survivalc (%)(2013-2017) (2013-2017) (2010-2016)

Site Total Males Females Total Males Females Total Males Females

All Sites 442.4 480.3 418.3 158.3 189.5 135.7 67.4 66.4 68.5

Oral Cavity & Pharynx: 11.4 17.2 6.4 2.5 3.9 1.3 66.2 65.6 67.7Lip 0.6 1.0 0.3 0.0 0.0 0.0 92.0 91.8 90.5Tongue 3.5 5.3 1.9 0.7 1.0 0.4 67.1 67.5 66.2Salivary gland 1.3 1.7 1.0 0.3 0.4 0.1 72.3 65.5 81.7Floor of mouth 0.5 0.7 0.3 0.0 0.0 0.0 51.1 49.0 55.8Gum & other oral cavity 1.5 1.9 1.3 0.4 0.5 0.3 59.8 57.0 63.3Nasopharynx 0.6 0.9 0.3 0.2 0.3 0.1 61.3 59.1 66.6Tonsil 2.0 3.5 0.7 0.2 0.4 0.1 75.1 75.4 73.1Oropharynx 0.5 0.8 0.2 0.3 0.4 0.1 49.0 51.1 41.0Hypopharynx 0.6 1.0 0.2 0.1 0.2 0.0 36.1 36.1 36.2Other oral cavity & pharynx 0.3 0.5 0.1 0.4 0.7 0.2 47.9 50.4 38.2

Digestive System: 81.0 98.5 66.4 40.9 52.4 31.4 43.6 41.3 46.6Esophagus 4.3 7.3 1.7 3.9 7.0 1.4 19.9 19.3 22.6Stomach 7.3 9.9 5.3 3.1 4.1 2.2 32.0 28.9 36.7Small intestine 2.4 2.8 2.1 0.4 0.5 0.3 68.3 68.1 68.5Colon & Rectum: 38.2 43.7 33.6 13.9 16.6 11.8 64.6 64.0 65.1Colon 26.8 29.5 24.6 - - - 63.4 63.2 63.6Rectum 11.4 14.3 9.1 - - - 67.1 65.6 69.1

Anus, anal canal & anorectum 1.9 1.6 2.2 0.3 0.2 0.3 68.7 63.7 71.5Liver & intrahepatic 9.0 13.8 4.8 6.6 9.6 4.0 19.6 19.3 20.5bile duct

Gallbladder 1.2 0.9 1.5 0.6 0.4 0.7 19.2 20.6 18.6Other biliary 1.9 2.3 1.5 0.4 0.5 0.4 18.7 19.7 17.5Pancreas 13.1 14.9 11.6 11.0 12.7 9.6 10.0 10.0 10.0Retroperitoneum 0.4 0.4 0.4 0.1 0.1 0.1 55.2 53.6 56.6Peritoneum, omentum & 0.5 0.1 0.8 0.3 0.1 0.4 32.4 36.5 32.2mesentery

Other digestive system 0.8 0.9 0.7 0.4 0.4 0.3 7.3 6.2 8.4

Respiratory System: 57.9 67.9 50.3 41.5 51.5 33.8 23.4 21.7 25.5Nose, nasal cavity & 0.7 0.9 0.5 0.1 0.2 0.1 58.1 58.3 57.6middle ear

Larynx 2.9 5.0 1.1 1.0 1.7 0.4 60.6 61.3 57.6Lung & bronchus 54.2 61.7 48.6 40.2 49.3 33.2 20.5 17.1 24.2Pleurad 0.0 0.0 0.0 0.1 0.1 0.0 24.3 17.3 34.2Trachea & other 0.2 0.3 0.1 0.1 0.1 0.1 54.9 54.0 57.4respiratory organs

Bones & joints 1.0 1.1 0.8 0.5 0.6 0.4 66.0 63.8 68.7

Soft tissue (including heart) 3.5 4.2 2.9 1.3 1.5 1.2 64.7 64.4 65.1

Skin (excl. basal & squamous): 24.7 32.2 19.3 3.4 5.3 1.9 92.0 90.3 94.4Melanoma of the skin 22.7 29.3 17.8 2.4 3.5 1.5 92.7 91.1 94.8Other non-epithelial skin 2.1 2.9 1.5 1.0 1.7 0.5 83.7 80.9 88.0

Breast 68.9 1.2 128.5 11.3 0.3 20.3 90.0 83.6 90.0

Breast (in situ) 17.4 0.1 33.0 - - - 100.0 100.0 100.0

Table 1.4Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival (Percent)

By Primary Cancer Site, Sex and Time Period

All Races

https://seer.cancer.gov/expsurvival/







d Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.e Due to coding changes, Brain & Nervous System mortality are no longer shown separately.f Rate not shown for mortality. Category did not exist in mortality coding until 1999.- Statistic could not be calculated due to less than 16 cases in the time interval.



Female Genital System: 27.2 - 51.3 8.2 - 15.1 70.0 - 70.0Cervix uteri 3.8 - 7.4 1.2 - 2.3 66.1 - 66.1Corpus uteri 14.3 - 27.0 1.2 - 2.3 82.7 - 82.7Uterus, NOS 0.5 - 0.9 1.4 - 2.6 28.5 - 28.5Ovaryd 6.0 - 11.2 3.8 - 6.9 48.6 - 48.6Vagina 0.4 - 0.7 0.1 - 0.2 48.5 - 48.5Vulva 1.4 - 2.6 0.3 - 0.5 70.4 - 70.4Other female genital system 0.9 - 1.7 0.2 - 0.4 50.8 - 50.8

Male Genital System: 53.7 116.9 - 8.1 19.6 - 97.5 97.5 -Prostate 50.2 109.8 - 7.8 19.1 - 97.8 97.8 -Testis 3.0 5.9 - 0.1 0.3 - 95.0 95.0 -Penis 0.4 0.9 - 0.1 0.2 - 65.4 65.4 -Other male genital system 0.1 0.3 - 0.0 0.0 - 82.8 82.8 -

Urinary System: 37.2 58.7 20.3 8.3 13.3 4.6 75.5 76.2 73.9Urinary bladder 20.0 34.9 8.6 4.4 7.5 2.1 76.9 78.3 72.4Kidney & renal pelvis 16.3 22.4 11.1 3.7 5.4 2.3 75.2 74.5 76.3Ureter 0.5 0.8 0.4 0.1 0.2 0.1 47.4 48.9 45.3Other urinary system 0.4 0.7 0.2 0.1 0.2 0.1 48.2 51.5 41.7

Eye & Orbit 0.9 1.0 0.8 0.1 0.1 0.1 83.2 83.6 82.6

Brain & Nervous System:e 6.4 7.5 5.4 4.4 5.4 3.6 32.6 31.3 34.2Brain 6.0 7.1 5.0 - - - 29.4 28.5 30.5Cranial nerves & other 0.4 0.4 0.4 - - - 80.1 78.0 82.1nervous system

Endocrine System: 16.5 9.0 23.8 0.8 0.8 0.8 96.6 92.8 97.9Thyroid 15.7 8.1 23.1 0.5 0.5 0.5 98.3 95.9 98.9Other endocrine & thymus 0.8 0.9 0.7 0.3 0.3 0.3 65.3 66.0 64.5

Lymphoma: 22.2 26.8 18.5 5.8 7.5 4.5 74.6 73.5 76.0Hodgkin lymphoma 2.6 2.9 2.3 0.3 0.4 0.2 87.4 86.5 88.6Non-Hodgkin lymphoma 19.6 23.8 16.2 5.5 7.1 4.2 72.7 71.5 74.2

Myeloma 7.0 8.8 5.7 3.3 4.1 2.6 53.9 53.7 54.1

Leukemia: 14.1 18.1 11.0 6.4 8.6 4.8 63.7 64.6 62.4Lymphocytic: 7.1 9.4 5.3 1.7 2.4 1.2 81.3 81.6 80.9Acute lymphocytic 1.7 2.0 1.5 0.4 0.5 0.4 68.8 68.4 69.2Chronic lymphocytic 5.0 6.8 3.5 1.2 1.7 0.8 86.1 85.9 86.3Other lymphocytic 0.4 0.6 0.2 0.1 0.2 0.1 82.4 85.3 73.2

Myeloid & Monocytic: 6.5 8.1 5.3 3.4 4.4 2.6 42.7 42.6 42.9Acute myeloid 4.3 5.2 3.6 2.8 3.6 2.2 28.7 27.7 29.9Chronic myeloid 1.9 2.5 1.5 0.3 0.4 0.2 70.4 69.5 71.6Acute monocytic 0.2 0.2 0.2 0.0 0.0 0.0 23.6 21.7 25.7Other myeloid & monocytic 0.1 0.2 0.1 0.2 0.4 0.2 38.7 40.7 36.0

Other leukemia: 0.5 0.6 0.4 1.3 1.8 1.0 34.1 35.4 32.5Other acute leukemia 0.2 0.3 0.2 0.4 0.6 0.3 25.9 27.9 23.6Aleukemic, subleukemic & NOS 0.3 0.3 0.2 0.9 1.2 0.7 40.4 41.6 39.1

Kaposi Sarcomaf 0.5 0.9 0.1 - - - 74.4 73.8 79.8Mesotheliomaf 0.9 1.6 0.4 - - - 10.1 7.7 17.1

Ill-defined & unspecified 7.5 8.7 6.5 11.6 14.6 9.4 18.6 22.0 15.0

Table 1.4 - continuedAge-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival (Percent)


All Races












All Sites 452.1 485.5 432.0 159.0 189.6 136.4 67.8 66.5 69.1

Oral Cavity & Pharynx: 12.0 18.1 6.6 2.5 3.9 1.4 67.6 67.3 68.3Lip 0.7 1.1 0.4 0.0 0.0 0.0 92.0 91.9 90.1Tongue 3.9 5.9 2.1 0.7 1.0 0.4 68.6 69.0 67.3Salivary gland 1.3 1.8 1.0 0.3 0.4 0.1 70.5 63.6 80.9Floor of mouth 0.5 0.7 0.3 0.0 0.0 0.0 52.3 50.2 56.9Gum & other oral cavity 1.6 1.9 1.3 0.4 0.5 0.3 59.8 57.2 62.9Nasopharynx 0.4 0.5 0.2 0.1 0.2 0.1 58.1 55.8 63.8Tonsil 2.3 3.9 0.8 0.3 0.4 0.1 76.3 76.6 74.7Oropharynx 0.5 0.8 0.2 0.3 0.4 0.1 52.1 54.7 41.7Hypopharynx 0.5 0.9 0.2 0.1 0.2 0.0 39.3 39.3 39.1Other oral cavity & pharynx 0.3 0.5 0.1 0.4 0.7 0.2 51.1 54.1 38.3






Larynx 2.9 5.1 1.1 0.9 1.7 0.4 61.7 62.3 59.2Lung & bronchus 56.0 62.2 51.5 41.0 49.4 34.5 20.6 17.2 24.2Pleurad 0.0 0.0 0.0 0.1 0.1 0.0 23.2 19.8 29.7Trachea & other 0.2 0.3 0.1 0.1 0.1 0.1 54.7 53.5 57.8respiratory organs

Bones & joints 1.0 1.2 0.9 0.5 0.6 0.4 66.0 63.5 69.3



Breast 69.5 1.2 131.3 10.9 0.3 19.8 90.9 85.7 90.9

Breast (in situ) 17.0 0.1 32.8 - - - 100.0 99.9 100.0



Whites














Eye & Orbit 1.0 1.1 0.9 0.1 0.1 0.1 82.7 82.9 82.6




Myeloma 6.4 8.2 5.0 3.0 3.9 2.4 52.7 52.8 52.5


Myeloid & Monocytic: 6.8 8.4 5.5 3.5 4.6 2.7 41.9 41.5 42.5Acute myeloid 4.4 5.4 3.7 2.9 3.7 2.2 28.3 27.2 29.6Chronic myeloid 2.0 2.6 1.5 0.3 0.4 0.2 69.3 68.2 70.9Acute monocytic 0.2 0.2 0.2 0.0 0.0 0.0 24.0 21.7 26.9Other myeloid & monocytic 0.1 0.2 0.1 0.3 0.4 0.2 36.7 38.1 34.7






Whites












All Sites 440.4 515.1 390.7 181.7 227.3 153.4 62.5 64.4 60.6

Oral Cavity & Pharynx: 8.5 13.3 4.9 2.7 4.5 1.3 49.5 47.6 53.8Lip 0.1 0.1 0.0 - - - 72.0 63.8 -Tongue 1.9 3.2 1.0 0.5 0.8 0.3 46.4 47.1 44.6Salivary gland 1.1 1.1 1.1 0.2 0.3 0.2 74.3 68.6 78.9Floor of mouth 0.4 0.7 0.2 0.0 0.1 - 40.2 40.1 39.1Gum & other oral cavity 1.2 1.5 1.0 0.3 0.5 0.2 53.7 48.7 58.9Nasopharynx 0.7 1.0 0.3 0.2 0.4 0.1 52.1 53.8 48.9Tonsil 1.6 2.9 0.6 0.2 0.4 0.1 58.9 59.5 56.0Oropharynx 0.6 1.0 0.3 0.4 0.6 0.2 31.7 31.1 32.4Hypopharynx 0.8 1.4 0.3 0.2 0.3 0.0 21.3 21.1 21.7Other oral cavity & pharynx 0.2 0.4 0.1 0.6 1.1 0.2 30.8 29.0 35.4






Larynx 3.9 7.3 1.4 1.6 3.0 0.5 51.7 52.6 48.7Lung & bronchus 54.8 71.2 43.8 42.3 58.8 31.1 18.4 15.1 22.3Pleurad - - - 0.0 0.1 0.0 - - -Trachea & other 0.2 0.2 0.1 0.1 0.1 0.0 49.9 47.2 55.3respiratory organs

Bones & joints 0.8 0.9 0.7 0.5 0.6 0.4 63.1 64.4 61.6



Breast 71.3 1.8 124.8 16.2 0.5 27.6 81.9 73.9 82.0

Breast (in situ) 18.6 0.2 33.0 - - - 100.0 95.2 100.0



Blacks














Eye & Orbit 0.3 0.3 0.3 0.0 0.0 0.0 88.1 85.4 90.1




Myeloma 13.8 16.5 12.0 6.2 7.5 5.3 56.8 56.3 57.3


Myeloid & Monocytic: 5.7 6.9 5.0 2.7 3.4 2.2 44.5 45.7 43.3Acute myeloid 3.7 4.4 3.3 2.2 2.7 1.9 28.6 27.7 29.5Chronic myeloid 1.8 2.2 1.5 0.3 0.4 0.2 71.6 72.7 70.2Acute monocytic 0.1 0.2 0.1 0.0 0.0 - 24.3 29.1 21.0Other myeloid & monocytic 0.1 0.2 0.1 0.2 0.3 0.1 38.3 42.0 31.2






Blacks



0

50

100

150

200

250

300

350

400

450

500

550

600

650

700

SEER Incidence US Mortality

Black White

010203040506070

Male

0

50

100

150

200

250

300

350

400

450

500

550

600

650

700

SEER Incidence US Mortality

010203040506070

Female

Figure 1.9

SEER Incidence and US Death Rates, 2013-20175-Year Relative Survival, 2010-2016

All Cancer Combined, by Race and Sex

a b

c

Incidence rates are from the SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry,Rural Georgia,California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts) and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).Death rates are from the US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).Survival rates are from the SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Males Females

Survival Survival

Rate per 100,000 Rate per 100,000

Percent (%) Percent (%)

a

b

c

SEE

R C

ancer Statistics Review

1975-2017N

ational Cancer Institute

99

98

95

92

91

88

84

77

77

75

73

68

67

67

64

64

62

53

48

31

31

21

21

19

10

10 15

10

17

18

14

32

39

41

57

52

59

57

63

56

50

68

76

64

65

63

85

82

67

92

96

97

Figure 1.11

5-Year Relative Survival (%)SEER Program, 2010-2016

Both Sexes, by Race and Cancer Site

White Patients Cancer Site Black Patients

Thyroid

Prostate

Testis

Melanoma of the Skin

Breast (Female)

Hodgkin Lymphoma

Corpus & Uterus, NOS

Kaposi Sarcoma

Urinary Bladder

Kidney & Renal Pelvis

Non-Hodgkin Lymphoma

Oral Cavity & Pharynx

Cervix Uteri

Rectum

Colon

Leukemia

Larynx

Myeloma

Ovary

Brain & ONS

Stomach

Esophagus

Lung & Bronchus

Liver & IBD

Pancreas

Mesothelioma

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.a

a


SEE

R C


1975-2017N


a Based on End Results data from a series of hospital registries and one population-based registry.b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2017. Expected survival rates are derived from the U.S. Annual Life Tables.c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey,

Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey andGeorgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and racedeveloped by the SEER program.Based on follow-up of patients into 2017.

d Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimatesfrom several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival),(2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

e The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).f The standard error is between 5 and 10 percentage points.g The standard error is greater than 10 percentage points.- Statistic could not be calculated due to fewer than 25 cases during the time period.

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

5-Year Relative Survival (Percent)Year of Diagnosis:1960-1963a - - - 39 - - 27 - -1970-1973a - - - 43 - - 31 - -1975-1977b 48.9 41.7 55.9 49.8 42.7 56.5 39.1 32.7 46.31978-1980b 49.0 43.1 54.9 50.0 44.3 55.6 39.0 33.3 45.61981-1983b 50.2 45.2 55.1 51.3 46.5 56.0 38.8 34.2 44.41984-1986b 52.4 47.1 57.6 53.6 48.6 58.6 40.2 35.5 45.51987-1989b 55.3 51.1 59.6 56.7 52.8 60.6 43.0 38.9 47.71990-1992b 59.9 59.1 60.9 61.4 60.8 62.1 47.9 47.7 48.21993-1995b 61.3 60.9 61.8 62.4 62.1 62.8 52.9 54.6 50.71996-1998b 63.3 63.0 63.6 64.4 64.1 64.7 55.4 58.1 52.21999-2001b 66.0 66.3 65.7 67.2 67.6 66.8 58.2 61.3 54.42002-2004b 67.1 67.7 66.5 68.4 69.0 67.7 59.8 63.5 55.52005-2009b 68.9 69.5 68.3 70.0 70.6 69.5 62.6 65.9 58.82010-2016b 69.5e 68.6e 70.5e 70.5e 69.5e 71.5e 64.1e 66.1e 62.1e

5-Year Period Survival (Percent)cd

2016 67.7 66.3 69.1 68.0 66.2 69.7 63.0 64.4 61.4

5-Year Relative Survival (Percent), 2010-2016c

Age at Diagnosis:Ages <45 83.3 79.4 85.8 84.6 80.9 87.0 74.1 69.2 76.9Ages 45-54 75.3 69.7 79.6 76.0 70.0 80.7 68.6 67.5 69.6Ages 55-64 70.1 68.6 71.9 70.9 69.0 73.1 63.8 65.5 61.4Ages 65-74 67.4 68.8 65.6 67.7 68.7 66.4 62.5 66.8 56.7Ages 75+ 50.8 52.8 49.0 51.5 52.9 50.1 44.4 48.7 41.1Ages <65 74.3 70.6 77.7 75.1 71.1 78.8 67.0 66.5 67.6Ages 65+ 60.1 62.4 57.5 60.4 62.2 58.3 55.8 61.2 49.8

Table 2.8All Cancer Sites (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age


SEE

R C


1975-2017N






e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.f The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).g The standard error is between 5 and 10 percentage points.h The standard error is greater than 10 percentage points.- Statistic could not be calculated due to fewer than 25 cases during the time period.


5-Year Relative Survival (Percent)Year of Diagnosis:1960-1963a - - - 18 16 21 19 17 211970-1973a - - - 20 18 22 19 19 191975-1977b 22.5 20.7 24.8 21.9 20.2 24.1 24.9 19.6 33.6g

1978-1980b 23.6 22.4 25.1 23.0 22.0 24.4 28.2 28.7 27.51981-1983b 24.2 23.1 25.5 23.4 22.5 24.6 30.8 31.7 29.2g

1984-1986b 26.9 25.6 28.5 26.2 24.8 27.9 30.9 32.8 28.51987-1989b 29.0 27.4 31.0 28.3 26.4 30.8 31.9 34.0 29.31990-1992b 30.1 30.5 29.7 29.1 29.4 28.8 39.3 40.2 38.11993-1995b 32.2 33.0 31.3 30.9 31.4 30.2 41.9 46.1 37.31996-1998b 31.3 30.7 32.0 30.6 30.2 31.0 36.0 33.7 38.31999-2001b 34.0 31.0 37.9 33.2 30.4 36.7 38.4 33.0 45.62002-2004b 35.1 34.2 36.2 34.2 33.8 34.6 39.5 33.4 45.82005-2009b 35.8 34.5 37.3 34.2 33.0 35.7 43.1 41.1 44.82010-2016b 33.4f 31.9f 35.3f 32.1f 30.7f 34.0f 39.5f 38.1f 41.0


2016 31.8 30.1 33.9 30.4 28.7 32.7 37.2 35.2 39.4

Stage Distribution (%) 2010-2016ce

All StagesNumber of cases 34,955 19,533 15,422 29,753 16,714 13,039 2,533 1,352 1,181Percent 100% 100% 100% 100% 100% 100% 100% 100% 100%Localized 77 77 77 77 78 77 75 77 74Regional 15 15 15 15 15 15 15 14 16Distant 2 3 2 2 2 2 3 3 4Unstaged/Unknown 6 5 6 5 5 6 7 7 7



Stagee:All Stages 32.6 31.3 34.2 31.3 30.0 33.0 38.9 37.2 40.7Localized 35.3 34.0 36.8 34.0 32.7 35.7 40.5 39.6 41.6Regional 20.3 19.2 21.7 19.1 18.3 20.1 26.9 21.3 32.4Distant 32.7 29.4 37.2 30.9 27.9 35.2 43.5g 39.3g 47.6g

Unstaged/Unknown 29.0 26.6 31.7 26.3 23.8 29.1 44.0 40.7g 47.6g

Table 3.8Cancer of the Brain and Other Nervous System (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age


SEE

R C


1975-2017N






e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.f The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).g The standard error is between 5 and 10 percentage points.h The standard error is greater than 10 percentage points.j In situ cases are not included in the All Stages group.- Statistic could not be calculated due to fewer than 25 cases during the time period.

All Races, Females White Females Black Females All <50 50+ All <50 50+ All <50 50+

5-Year Relative Survival (Percent)Year of Diagnosis:1960-1963a - - - 63 - - 46 - -1970-1973a - - - 68 - - 51 - -1975-1977b 74.8 76.5 74.3 75.6 77.8 74.9 62.2 62.4 62.01978-1980b 74.4 75.5 74.1 75.1 76.1 74.9 63.4 67.0 61.51981-1983b 76.1 77.4 75.7 77.1 78.6 76.7 63.4 65.0 62.61984-1986b 78.9 77.8 79.3 80.0 79.5 80.1 65.1 64.0 65.91987-1989b 84.0 81.4 84.9 85.1 82.7 85.9 71.1 69.6 71.91990-1992b 85.2 83.4 85.9 86.5 85.1 86.9 71.5 70.1 72.41993-1995b 86.4 84.3 87.1 87.6 86.2 88.1 72.8 70.5 74.21996-1998b 88.2 86.6 88.8 89.3 88.3 89.7 76.3 74.1 77.61999-2001b 89.7 88.1 90.3 90.8 89.9 91.1 79.0 77.0 80.12002-2004b 90.0 89.3 90.2 91.4 91.1 91.5 78.0 77.6 78.22005-2009b 90.9 91.2 90.9 92.2 92.5 92.1 81.2 82.4 80.62010-2016b 91.4f 91.2f 91.5f 92.5f 92.5f 92.5f 83.4f 82.6f 83.8f

5-Year Period Survival (Percent)cd2016 90.3 90.0 90.4 91.2 91.1 91.2 82.6 81.5 83.0

Stage Distribution (%) 2010-2016ceAll StagesNumber of cases 356,026 79,017 277,009 278,199 57,351 220,848 40,580 10,659 29,921Percent 100% 100% 100% 100% 100% 100% 100% 100% 100%Localized 63 55 65 64 55 66 55 48 57Regional 30 39 27 29 38 27 35 42 32Distant 6 5 6 6 5 6 9 9 9Unstaged/Unknown 2 1 2 1 1 2 2 2 2

5-Year Relative Survival (Percent), 2010-2016cAge at Diagnosis:Ages <45 88.1 - - 89.3 - - 79.2 - -Ages 45-54 91.1 - - 92.2 - - 82.8 - -Ages 55-64 90.5 - - 91.5 - - 83.0 - -Ages 65-74 92.1 - - 92.8 - - 85.3 - -Ages 75+ 86.0 - - 87.0 - - 76.8 - -Ages <65 90.2 - - 91.3 - - 82.1 - -Ages 65+ 89.7 - - 90.4 - - 82.0 - -

Stagee:All Stages 90.0 89.7 90.1 90.9 90.9 90.9 82.0 81.1 82.4Localized 98.9 97.1 99.3 99.2 97.4 99.6 96.1 94.0 96.8Regional 85.7 87.3 85.0 86.8 88.6 86.1 77.7 78.6 77.3Distant 28.1 37.6 25.6 29.4 40.8 26.8 19.4 26.2 16.9Unstaged/Unknown 55.1 75.1 50.4 52.7 74.9 48.5 50.3 69.6 43.0In Situ j 100.0 100.0 100.0 100.0 100.0 100.0 100.0 99.9 100.0

Table 4.13Cancer of the Female Breast (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Diagnosis Year, Stage and Age


SEE

R C


1975-2017N








5-Year Relative Survival (Percent)Year of Diagnosis:1960-1963a - - - 58 - - 47 - -1970-1973a - - - 64 - - 61 - -1975-1977b 69.1 82.6 57.8 69.7 84.0 58.1 64.7 75.6 55.11978-1980b 67.4 78.4 57.8 68.1 79.8 58.2 61.1 70.7 51.91981-1983b 66.9 79.6 54.6 67.8 80.8 54.9 59.2 73.6 46.21984-1986b 67.2 77.9 55.3 68.8 79.4 56.4 57.8 68.0 48.11987-1989b 70.0 79.6 58.0 72.5 82.6 58.4 56.9 62.7 51.81990-1992b 69.7 79.2 56.8 71.0 81.4 56.4 58.1 63.8 51.01993-1995b 72.6 81.8 59.9 74.2 83.5 60.1 62.8 70.6 53.61996-1998b 72.7 81.0 60.5 73.7 82.7 59.2 65.2 67.8 62.11999-2001b 72.4 84.0 56.2 73.3 85.7 54.9 66.2 74.1 56.92002-2004b 69.3 79.3 55.8 70.3 81.3 54.5 64.5 72.3 54.82005-2009b 70.0 80.2 56.7 71.4 82.6 56.1 61.1 67.2 54.82010-2016b 69.7 79.9f 57.5 71.5 82.2 58.4 57.9f 69.0 46.5f


2016 65.9 76.5 54.3 66.8 77.3 54.6 56.6 67.6 46.7




Age at Diagnosis:Ages <45 78.5 - - 79.9 - - 68.0 - -Ages 45-54 66.8 - - 68.1 - - 58.2 - -Ages 55-64 57.6 - - 58.2 - - 46.3 - -Ages 65-74 52.4 - - 52.3 - - 48.1 - -Ages 75+ 34.7 - - 35.9 - - 27.5 - -Ages <65 70.4 - - 71.8 - - 59.7 - -Ages 65+ 45.4 - - 46.1 - - 39.4 - -

Stagee:All Stages 66.1 76.2 54.8 67.5 77.8 55.5 55.6 65.8 46.1Localized 91.8 93.9 87.7 92.3 94.4 87.9 87.6 90.8 82.3Regional 57.6 62.2 53.9 58.8 63.9 54.5 49.7 54.7 45.5Distant 16.8 19.6 15.4 18.2 21.9 16.4 10.5 9.9 11.1Unstaged/Unknown 49.7 72.7 33.9 49.1 73.3 31.7 47.4 64.8g 36.2g

Table 5.8Cancer of the Cervix Uteri (Invasive)



SEE

R C


1975-2017N








5-Year Relative Survival (Percent)Year of Diagnosis:1960-1963a - - - - - - - - -1970-1973a - - - - - - - - -1975-1977b 49.8 48.9 50.6 50.1 49.3 50.8 44.8 43.4 46.01978-1980b 51.2 50.2 52.1 51.6 50.6 52.5 45.4 43.4 46.91981-1983b 54.0 53.7 54.2 54.3 54.3 54.3 46.5 42.9 49.51984-1986b 57.7 57.7 57.6 58.4 58.5 58.3 48.4 47.5 49.11987-1989b 59.6 59.8 59.3 60.0 60.6 59.5 52.3 49.8 54.51990-1992b 61.2 61.0 61.3 61.9 61.7 62.1 52.8 54.4 51.41993-1995b 59.9 59.7 60.0 60.5 60.3 60.6 51.8 51.4 52.01996-1998b 62.4 62.3 62.4 63.0 62.8 63.1 54.0 55.3 53.01999-2001b 65.1 66.1 64.1 66.5 67.4 65.6 54.4 56.0 53.12002-2004b 65.8 65.7 65.8 66.7 67.1 66.4 56.6 55.5 57.52005-2009b 66.7 66.8 66.6 67.5 67.8 67.1 59.5 57.4 61.22010-2016b 66.1f 66.0f 66.3f 66.8f 66.8f 66.8f 59.6f 59.0f 60.1f


2016 65.0 64.4 65.6 65.3 64.8 65.9 59.3 57.1 61.5





Stagee:All Stages 64.6 64.0 65.1 65.0 64.5 65.5 58.8 56.8 60.6Localized 90.2 89.4 90.9 90.3 89.5 91.3 87.4 86.2 88.4Regional 71.8 71.5 72.0 72.3 72.2 72.3 67.5 65.6 69.2Distant 14.3 13.3 15.5 14.9 13.9 16.0 10.5 9.4 11.6Unstaged/Unknown 37.5 41.1 34.0 33.4 37.6 29.4 39.7 40.0 39.0

Table 6.12Cancer of the Colon and Rectum (Invasive)



SEE

R C


1975-2017N








5-Year Relative Survival (Percent)Year of Diagnosis:1960-1963a - - - 43 42 44 34 32 351970-1973a - - - 49 47 50 37 36 381975-1977b 50.6 50.1 51.1 50.9 50.5 51.3 44.9 44.2 45.51978-1980b 52.3 51.2 53.1 52.4 51.3 53.4 48.9 47.5 49.81981-1983b 55.2 55.6 54.7 55.4 56.2 54.7 48.5 44.7 51.51984-1986b 58.3 58.8 57.8 59.0 59.6 58.5 49.2 48.9 49.31987-1989b 60.2 60.7 59.6 60.6 61.4 59.9 52.3 50.6 53.81990-1992b 62.0 62.3 61.7 62.7 63.1 62.4 53.3 54.6 52.31993-1995b 59.8 60.1 59.5 60.5 60.7 60.2 51.2 51.3 50.91996-1998b 62.1 62.3 61.8 62.8 62.8 62.8 53.7 56.0 51.81999-2001b 64.9 66.1 63.7 66.6 67.9 65.5 52.8 54.3 51.62002-2004b 64.8 64.6 64.9 65.7 65.7 65.7 55.6 55.1 56.02005-2009b 66.0 66.4 65.6 67.2 67.8 66.7 57.2 56.4 57.92010-2016b 64.7f 64.9f 64.5f 65.9f 66.1f 65.7f 56.5f 57.4f 55.8f


2016 63.8 63.5 64.0 64.6 64.2 64.9 57.3 56.3 58.3






Table 6.13Cancer of the Colon (Invasive)



SEE

R C


1975-2017N










2016 67.6 66.0 69.8 67.0 65.8 68.8 64.6 59.0 71.1






Table 6.14Cancer of the Rectum (Invasive)



SEE

R C


1975-2017N








5-Year Relative Survival (Percent)Year of Diagnosis:1960-1963a - - - 73 - - 31 - -1970-1973a - - - 81 - - 44 - -1975-1977b 86.9 92.7 86.2 88.0 93.3 87.4 60.3 84.4g 55.81978-1980b 82.5 91.7 81.3 83.7 93.1 82.6 54.9 82.3g 49.51981-1983b 80.7 91.2 79.4 82.2 92.3 81.1 50.7 82.8g 45.61984-1986b 82.5 93.6 81.0 84.0 93.9 82.8 56.2 83.5g 52.71987-1989b 82.2 89.8 81.1 83.9 90.9 82.9 56.7 82.8g 52.91990-1992b 83.6 90.1 82.6 85.8 92.2 84.9 54.0 72.9g 50.21993-1995b 83.2 90.0 82.0 84.9 91.5 83.8 58.6 81.7 54.01996-1998b 83.5 90.1 82.4 85.2 91.3 84.2 61.7 82.2 57.31999-2001b 84.2 88.8 83.3 85.9 89.9 85.2 61.4 71.2 58.92002-2004b 83.0 90.1 81.5 85.3 92.5 84.0 60.4 78.0 55.92005-2009b 83.6 88.3 82.7 85.7 89.8 85.1 65.8 76.4 63.82010-2016b 82.9f 89.2f 82.0f 85.5f 90.4f 84.9f 64.8f 82.2 62.1f


2016 81.3 88.6 80.1 83.5 89.4 82.7 63.9 80.3 61.5





Stagee:All Stages 81.2 88.2 80.1 83.5 89.3 82.7 62.7 79.1 60.3Localized 95.0 96.6 94.7 95.9 96.9 95.7 86.5 92.9 85.4Regional 69.4 81.5 67.8 72.0 82.7 70.7 49.9 71.7 47.3Distant 17.3 30.5 15.5 18.8 31.4 17.1 10.4 26.6 8.5Unstaged/Unknown 53.2 87.3 46.3 52.2 87.8 46.2 44.5 79.8g 38.9

Table 7.8Cancer of the Corpus and Uterus, NOS (Invasive)



SEE

R C


1975-2017N










2016 20.4 19.6 23.6 20.9 20.2 23.8 15.6 14.7 17.2


All StagesNumber of cases 21,743 17,264 4,479 18,248 14,746 3,502 2,163 1,488 675Percent 100% 100% 100% 100% 100% 100% 100% 100% 100%Localized 18 17 21 18 18 22 16 14 20Regional 33 33 33 33 33 32 33 33 33Distant 39 41 33 39 41 32 40 43 34Unstaged/Unknown 10 9 14 9 8 14 11 10 13


Age at Diagnosis:Ages <45 23.1 21.1 31.0 23.1 22.8 24.3g 20.0g - -Ages 45-54 21.3 20.1 27.5 22.2 21.1 29.0 15.1 14.5 16.2Ages 55-64 20.4 19.4 25.6 21.7 20.8 27.4 12.9 10.2 19.3Ages 65-74 23.4 22.4 27.8 24.3 23.2 29.5 15.1 13.6 17.8Ages 75+ 13.9 13.8 14.3 13.6 13.6 13.7 12.0 12.2 11.3Ages <65 20.8 19.7 26.5 22.0 21.0 27.7 13.9 11.4 20.0Ages 65+ 19.2 18.9 20.2 19.6 19.3 20.4 14.1 13.3 15.1

Stagee:All Stages 19.9 19.3 22.6 20.6 20.1 22.8 14.0 12.2 17.7Localized 47.1 49.2 40.6 48.6 50.9 40.8 32.2 29.6 35.7g

Regional 25.2 24.3 29.3 25.9 25.0 29.7 19.8 18.4 22.0Distant 4.9 4.2 8.5 4.9 4.4 8.2 3.3 2.2 6.0Unstaged/Unknown 12.8 12.9 12.7 12.7 12.7 12.6 10.2 10.5 10.1

Table 8.8Cancer of the Esophagus (Invasive)



SEE

R C


1975-2017N








5-Year Relative Survival (Percent)Year of Diagnosis:1960-1963a - - - 40 34 48 - - -1970-1973a - - - 67 66 69 - - -1975-1977b 71.8 69.9 74.3 72.1 70.1 74.5 70.1 68.5g 73.3g

1978-1980b 71.6 70.3 73.4 71.7 69.8 74.2 70.6 74.7g 63.1g

1981-1983b 74.3 72.9 76.0 74.6 73.7 75.7 71.8 69.6g 75.9g

1984-1986b 78.4 76.6 80.7 78.8 77.0 81.2 74.9 76.0g 72.1g

1987-1989b 79.2 76.6 82.5 79.7 76.8 83.3 72.3 70.9g 74.0g

1990-1992b 81.7 79.3 84.6 82.8 81.1 84.9 74.3 65.2 84.31993-1995b 81.7 79.3 84.6 82.2 80.0 84.7 78.4 74.2 83.01996-1998b 85.2 84.5 85.9 85.8 84.5 87.3 81.2 84.4 77.71999-2001b 85.1 82.8 87.9 85.7 84.0 87.8 81.6 75.6 89.72002-2004b 86.2 85.2 87.2 87.7 86.9 88.5 79.2 74.4 82.82005-2009b 88.2 87.2 89.5 88.7 88.3 89.3 85.3 81.2 90.02010-2016b 89.6f 88.3f 91.3f 90.3f 89.1f 91.7f 86.7f 83.5f 90.8f


2016 87.5 86.5 88.9 87.9 86.8 89.4 84.5 83.0 86.2




Age at Diagnosis:Ages <45 95.1 94.6 95.7 95.8 95.5 96.2 90.7 88.2 93.4Ages 45-54 87.2 85.2 90.6 88.5 86.9 91.2 81.8 78.8 85.8Ages 55-64 79.5 78.2 81.4 80.5 79.4 81.8 70.1 66.6g 73.7g

Ages 65-74 67.0 64.1 70.8 66.4 62.8 71.0 72.8g 75.5g 67.9g

Ages 75+ 49.4 50.8 48.0 49.5 49.3 49.3 52.9g - -Ages <65 91.9 90.7 93.4 92.7 91.7 93.9 86.7 84.0 90.0Ages 65+ 59.6 59.0 60.1 59.2 57.5 60.8 67.9g 73.6g 61.5g

Stagee:All Stages 87.4 86.5 88.6 87.5 86.6 88.6 85.4 83.3 87.7Localized 91.3 92.2 90.0 91.1 91.8 90.0 90.9 92.4 88.8Regional 93.8 92.7 94.9 93.9 92.7 95.0 92.8 90.4 94.3Distant 80.6 80.4 80.8 80.7 80.8 80.4 79.2 76.9 82.8Unstaged/Unknown 81.3 79.1 83.9 79.7 76.1 84.5 78.3g 84.1g 71.8g

Table 9.8Hodgkin Lymphoma



SEE

R C


1975-2017N








5-Year Relative Survival (Percent)Year of Diagnosis:1960-1963a - - - - - - - - -1970-1973a - - - - - - - - -1975-1977b 80.7f 80.1f - 79.9f 79.0f - - - -1978-1980b 78.3f 79.4f 73.1g 78.0f 78.4f 72.5g - - -1981-1983b 35.7 33.4 64.3g 34.0 31.6 64.2g - - -1984-1986b 13.0 11.7 70.5g 12.8 11.4 70.2g 16.8 15.7 -1987-1989b 9.9 9.3 68.5g 9.4 8.8 72.4g 12.4 11.3 -1990-1992b 9.3 8.6 53.9f 8.9 8.2 55.4f 11.8 10.8 -1993-1995b 21.8 21.1 53.8f 22.1 21.3 62.1g 17.5 16.7 -1996-1998b 52.4 51.6 71.4g 57.1 55.9 85.9f 40.2 39.7 -1999-2001b 58.3 57.9 60.0f 64.8 63.3 78.4g 44.1 45.6 -2002-2004b 64.7 63.8 71.1g 75.2 74.1 76.9g 42.0 42.2 -2005-2009b 74.3 74.5 70.7f 81.4 81.5 76.0f 59.8 60.2 -2010-2016b 76.3e 76.2 75.3f 82.0 81.1 83.7f 66.0 67.6 37.9g


2016 74.6 73.8 80.7 77.6 75.5 90.7 63.5 65.3 33.4


Age at Diagnosis:Ages <45 68.4 69.1 46.2f 70.3 70.3 - 64.4 65.5 39.1g

Ages 45-54 73.1 73.6 - 75.9 75.7 - 61.9 64.1 -Ages 55-64 81.4 82.1 - 83.0 82.4 - 75.3f 82.6f -Ages 65-74 84.7 83.4 85.4f 82.7 80.3 87.9f - - -Ages 75+ 85.2 76.9f 86.0f 85.9f 77.1f 86.9f - - -Ages <65 71.6 72.2 55.0f 74.6 74.3 82.2f 64.6 66.3 34.0f

Ages 65+ 85.7 81.2 86.6 85.2 79.6 87.9f 65.7g - -

Table 10.6Kaposi Sarcoma



SEE

R C


1975-2017N









1978-1980b 52.9 52.7 53.3 52.6 52.9 52.1 56.9 51.9 62.8g

1981-1983b 50.1 51.1 48.3 49.9 51.2 47.7 50.6 50.2 51.21984-1986b 54.5 55.0 53.7 54.6 55.3 53.5 52.6 49.2 57.51987-1989b 56.7 57.0 56.1 57.3 58.0 56.1 54.8 53.0 57.01990-1992b 60.2 60.5 59.6 60.6 61.2 59.7 57.0 55.2 59.11993-1995b 61.5 61.7 61.1 62.0 62.9 60.7 57.6 54.2 62.11996-1998b 62.6 62.9 62.0 62.1 62.6 61.2 67.1 68.2 64.81999-2001b 64.9 63.4 67.2 64.9 63.7 66.9 64.1 59.4 69.42002-2004b 69.3 69.5 68.9 69.4 69.8 68.7 65.7 65.0 66.72005-2009b 74.8 74.0 76.2 74.8 74.0 76.2 74.6 73.6 76.12010-2016b 75.9f 75.2f 76.9f 75.7f 75.0f 76.7f 77.9f 77.5f 78.6f


2016 75.8 75.0 77.0 75.8 74.9 77.3 75.8 75.2 76.8






Table 11.8Cancer of the Kidney and Renal Pelvis (Invasive)



SEE

R C


1975-2017N








5-Year Relative Survival (Percent)Year of Diagnosis:1960-1963a - - - 53 54 46 - - -1970-1973a - - - 62 63 56 - - -1975-1977b 66.0 66.6 62.5 66.7 67.4 62.3 58.2 57.1 63.3g

1978-1980b 65.3 65.5 64.6 66.2 66.4 65.4 56.9 57.2 55.8g

1981-1983b 68.1 68.4 66.9 69.5 69.7 68.5 56.5 57.7 50.8g

1984-1986b 65.2 65.7 62.2 66.9 67.4 64.0 53.3 53.7 51.1g

1987-1989b 65.5 66.6 61.0 67.0 68.5 60.8 56.1 54.3 61.3g

1990-1992b 65.8 66.7 62.6 67.7 68.4 64.6 53.7 54.3 51.3g

1993-1995b 63.6 65.2 56.6 65.2 67.0 57.9 53.1 54.4 47.4g

1996-1998b 64.8 66.5 58.8 66.8 68.4 61.2 53.7 56.6 45.0g

1999-2001b 63.3 64.2 59.8 65.3 66.3 61.1 49.8 49.1 52.4g

2002-2004b 61.8 62.1 60.7 64.3 64.2 64.9 50.8 53.6 41.4g

2005-2009b 63.1 63.5 61.2 65.1 65.6 63.1 50.9 51.1 49.7g

2010-2016b 62.1f 62.9f 58.7 63.6f 64.3 60.8 52.7 54.1 47.6


2016 61.3 62.3 57.6 62.3 63.1 58.9 53.5 54.4 50.2




Age at Diagnosis:Ages <45 79.1 75.5 88.4 81.7 77.8 91.1 68.6g 67.8g -Ages 45-54 60.9 60.8 61.1 62.7 62.1 64.6 52.8 54.3 48.2g

Ages 55-64 61.0 61.3 59.6 62.2 62.6 60.5 52.7 52.7 52.6Ages 65-74 59.1 60.4 52.9 59.9 60.9 54.8 48.9 51.2 39.4g

Ages 75+ 58.9 61.3 49.0 59.9 62.3 49.0 45.9g 46.7g 43.3h

Ages <65 62.0 61.9 62.5 63.5 63.2 64.5 53.6 54.0 52.3Ages 65+ 58.9 60.7 51.3 59.8 61.4 52.7 48.2 50.1 41.4g

Stagee:All Stages 60.6 61.3 57.6 61.7 62.3 59.2 51.7 52.6 48.7Localized 77.7 78.8 72.8 78.2 78.9 74.5 70.9 73.3 61.2Regional 45.4 44.3 48.3 46.2 45.4 48.5 40.6 37.5 47.9Distant 33.8 33.3 36.1 33.6 32.9 36.4 33.0 33.1 33.0Unstaged/Unknown 52.7 54.7 40.0g 51.9 53.5 41.4g 37.3g 37.0g -

Table 12.8Cancer of the Larynx (Invasive)



SEE

R C


1975-2017N








5-Year Relative Survival (Percent)Year of Diagnosis:1960-1963a - - - 14 - - - - -1970-1973a - - - 22 - - - - -1975-1977b 34.2 33.0 35.6 34.6 33.5 35.8 33.4 30.4 36.71978-1980b 36.0 35.0 37.4 36.7 35.7 38.1 28.2 27.3 29.31981-1983b 37.3 36.9 37.8 38.1 37.7 38.5 33.9 33.4 34.31984-1986b 40.5 40.1 41.1 41.6 41.3 42.0 32.7 31.5 34.11987-1989b 42.9 44.0 41.3 43.9 45.5 41.8 35.0 32.7 37.81990-1992b 45.2 44.6 46.0 46.5 46.3 46.8 35.7 30.5 41.31993-1995b 47.6 48.5 46.4 48.7 49.6 47.5 41.3 41.6 40.91996-1998b 48.4 48.7 48.1 49.8 49.8 49.9 38.6 39.0 38.01999-2001b 51.0 52.0 49.7 52.1 53.1 50.8 43.9 45.1 42.52002-2004b 58.3 58.4 58.1 59.1 59.4 58.8 53.9 54.5 53.12005-2009b 62.7 64.0 60.9 63.9 64.9 62.4 56.0 59.7 51.22010-2016b 66.4e 67.6e 64.8e 67.3e 68.3e 65.9e 62.5e 64.2e 60.7e


2016 64.3 65.2 63.1 64.5 64.8 64.0 60.6 64.1 56.7



Table 13.14Leukemia



SEE

R C


1975-2017N


a SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).Based on follow-up of patients into 2017. Expected survival rates are derived from the U.S. Annual Life Tables.

b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey,Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey andGeorgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and racedeveloped by the SEER program.Based on follow-up of patients into 2017.

c Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimatesfrom several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival),(2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

d The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).e The standard error is between 5 and 10 percentage points.f The standard error is greater than 10 percentage points.- Statistic could not be calculated due to fewer than 25 cases during the time period.


Acute Lymphocytic Leukemia5-Year Relative Survival (Percent)Year of Diagnosis:1975-1977a 40.6 36.9 45.6 40.8 37.4 45.7 33.5e - -...1987-1989a 54.4 53.7 55.2 55.0 54.8 55.3 44.7e 42.0e 47.1e1990-1992a 58.0 54.5 63.1 57.7 54.9 62.0 57.1e 50.4e 63.3e1993-1995a 60.2 57.8 63.5 59.8 57.8 62.6 53.2e 45.9e 63.8e1996-1998a 65.5 64.4 66.9 66.4 64.3 69.1 55.6e 59.1e 50.2e1999-2001a 63.5 63.4 63.7 64.8 65.2 64.3 56.6e 50.3e 63.0e2002-2004a 67.3 66.2 68.8 67.6 66.6 69.0 64.5e 59.4e 69.7e2005-2009a 69.9 69.0 71.2 70.8 69.3 72.8 62.6 67.6 53.0e2010-2016a 72.1d 72.6d 71.6d 71.9d 72.9d 70.8d 66.4d 64.0 69.1

5-Year Period Survival (Percent)bc2016 69.0 68.1 70.1 68.4 66.8 70.6 67.5 67.6 67.0

5-Year Relative Survival (Percent), 2010-2016bAge at Diagnosis:Ages <45 80.7 79.4 82.4 80.6 78.9 83.0 77.1 76.0 78.6Ages 45-54 39.0 37.7 40.8 37.2 36.9 38.0 34.9e - -Ages 55-64 31.5 32.5 30.5 32.3 33.0 31.4 22.1e 28.2e 13.7eAges 65-74 24.1 19.3 28.6 24.1 18.0 30.0 - - -Ages 75+ 11.1 10.0 12.0 11.1 9.0 12.9 - - -Ages <65 73.5 72.8 74.5 73.4 72.3 74.8 68.5 67.8 69.3Ages 65+ 18.3 15.5 20.7 18.5 14.4 22.4 12.8e - 11.6e

Chronic Lymphocytic Leukemia5-Year Relative Survival (Percent)Year of Diagnosis:1975-1977a 67.1 64.7 70.4 67.9 65.3 71.3 56.9e 55.1e 59.0e...1987-1989a 72.7 72.6 72.7 73.8 74.0 73.5 58.1 55.5e 61.5e1990-1992a 74.1 71.8 77.3 75.3 73.2 78.4 52.2 43.4e 60.9e1993-1995a 77.2 77.1 77.3 78.4 78.2 78.6 63.3 64.0e 62.1e1996-1998a 75.6 74.0 77.7 76.7 75.3 78.6 58.1 51.5e 66.0e1999-2001a 78.7 78.2 79.4 79.5 79.0 80.5 66.8 65.5e 67.1e2002-2004a 84.0 83.1 85.1 84.4 83.6 85.6 77.0 74.2e 80.7e2005-2009a 86.3 86.3 86.4 86.6 86.6 86.8 84.3 85.7 81.82010-2016a 88.6d 88.6d 88.8d 89.0d 88.6d 89.6d 81.2d 83.2d 78.5


5-Year Relative Survival (Percent), 2010-2016bAge at Diagnosis:Ages <45 93.7 92.3 95.8 94.5 93.6 95.4 87.8e 84.5e -Ages 45-54 94.0 94.1 93.7 94.5 94.3 94.8 85.6 88.3 80.3eAges 55-64 92.7 92.1 93.8 93.0 92.1 94.8 84.9 86.4 82.5Ages 65-74 88.6 87.0 91.4 88.6 86.4 92.3 82.7 84.5 79.3Ages 75+ 74.3 73.3 75.3 73.9 72.4 75.3 64.0 67.6e 60.8eAges <65 93.1 92.7 93.9 93.5 92.8 94.9 85.4 87.0 82.7Ages 65+ 81.4 80.8 82.2 81.1 80.0 82.5 74.9 79.1 70.2

Table 13.15Lymphocytic Leukemia



SEE

R C


1975-2017N





d The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).e The standard error is between 5 and 10 percentage points.f The standard error is greater than 10 percentage points.- Statistic could not be calculated due to fewer than 25 cases during the time period.


Acute Myeloid Leukemia5-Year Relative Survival (Percent)Year of Diagnosis:1975-1977a 6.2 5.5 6.9 5.8 5.4 6.2 10.1 8.2 11.7...1987-1989a 11.5 9.2 14.1 11.3 9.7 13.2 9.2 4.4 15.7e1990-1992a 13.8 12.6 15.2 13.5 12.2 15.0 13.5 12.9 13.91993-1995a 16.1 15.0 17.3 15.3 14.2 16.6 21.5 20.6e 22.01996-1998a 17.0 15.9 18.4 15.7 14.5 17.2 22.1 25.2 18.21999-2001a 19.2 18.8 19.7 18.7 17.6 19.9 19.3 24.8 14.22002-2004a 23.4 20.9 26.4 23.2 20.8 26.0 25.3 26.5 24.02005-2009a 25.5 25.0 26.2 24.9 24.3 25.6 25.5 22.3 28.12010-2016a 29.8d 28.9d 30.9d 29.3d 28.0d 30.8d 30.5d 29.3d 31.6d


5-Year Relative Survival (Percent), 2010-2016bAge at Diagnosis:Ages <45 61.5 60.4 62.7 63.2 61.8 64.6 53.8 51.1 56.1Ages 45-54 45.3 44.4 46.4 46.6 45.5 47.9 36.4 35.8 37.2Ages 55-64 30.4 28.1 33.5 31.5 28.5 35.6 19.1 21.2 16.2Ages 65-74 14.8 14.5 15.3 15.5 15.5 15.5 9.5 4.5 14.1Ages 75+ 3.2 3.8 2.4 3.2 3.8 2.5 2.6 5.5 0.9Ages <65 47.5 45.2 50.2 48.4 45.7 51.6 40.2 38.4 42.0Ages 65+ 8.2 8.8 7.6 8.5 9.2 7.7 6.0 4.7 7.1

Chronic Myeloid Leukemia5-Year Relative Survival (Percent)Year of Diagnosis:1975-1977a 21.8 19.3 25.1 20.5 18.4 23.4 27.7e 21.6e 35.5e...1987-1989a 30.3 30.6 29.8 30.1 31.0 29.0 33.3e 28.1e 41.3e1990-1992a 30.6 29.6 31.9 30.1 30.0 30.3 34.9e 25.5e 44.9e1993-1995a 35.5 35.2 35.9 35.1 35.0 35.2 35.6e 32.8e 40.2e1996-1998a 37.2 37.7 36.4 38.1 37.6 38.5 31.0 30.4e 31.4e1999-2001a 47.3 45.9 49.3 45.9 44.1 48.3 49.5e 49.6e 49.3e2002-2004a 54.4 53.1 56.2 52.8 51.5 54.4 62.9e 63.3e 61.9e2005-2009a 63.4 63.4 63.5 62.5 62.2 63.0 61.4 63.3e 58.1e2010-2016a 71.7d 70.1d 73.7d 70.7d 69.4d 72.3d 78.3d 75.7d 80.7d


5-Year Relative Survival (Percent), 2010-2016bAge at Diagnosis:Ages <45 90.1 89.3 91.3 91.4 90.8 92.3 82.1 80.3 84.6Ages 45-54 89.2 87.2 92.1 88.6 86.6 91.5 90.3 87.7 92.5Ages 55-64 77.7 76.2 80.0 78.1 75.4 81.9 69.1 76.2e 60.8eAges 65-74 61.3 58.4 65.2 61.1 57.9 65.9 57.5e 53.5e 61.3eAges 75+ 36.7 33.6 39.3 36.7 34.0 38.9 35.4e 34.6f 35.1eAges <65 85.8 84.5 87.6 86.0 84.4 88.4 80.8 81.5 79.7Ages 65+ 48.6 46.8 50.9 48.2 46.4 50.6 48.8 47.4e 50.2e

Table 13.16Myeloid Leukemia



SEE

R C


1975-2017N








5-Year Relative Survival (Percent)Year of Diagnosis:1960-1963a - - - - - - - - -1970-1973a - - - - - - - - -1975-1977b 3.4 1.8 6.3 3.4 2.0 5.8 1.8 0.0 5.61978-1980b 3.3 2.2 5.4 3.3 2.2 4.8 3.6 3.0 5.01981-1983b 3.7 2.9 5.2 4.0 3.0 5.5 2.8 2.1 4.71984-1986b 5.6 3.6 9.5 5.7 3.7 9.1 4.4 2.1 9.11987-1989b 4.9 3.2 8.0 5.7 3.4 9.4 2.7 1.6 4.91990-1992b 5.6 5.0 7.0 6.3 5.1 8.3 2.6 2.0 3.61993-1995b 5.5 5.3 6.0 5.2 4.9 5.7 4.0 2.8 7.31996-1998b 8.6 8.3 9.1 8.4 7.6 10.2 4.6 5.9 2.01999-2001b 11.3 10.9 12.1 10.3 9.6 11.7 7.6 6.8 9.52002-2004b 14.8 14.9 14.7 14.1 14.6 13.0 9.6 7.3 15.82005-2009b 17.6 17.7 17.3 16.8 17.1 16.2 12.7 12.4 13.62010-2016b 20.8f 20.8f 20.9f 19.9f 20.2f 19.0f 18.7f 18.3 19.7f


2016 20.6 20.3 21.1 19.5 19.5 19.8 18.4 17.8 19.9




Age at Diagnosis:Ages <45 41.6 39.0 46.2 49.3 47.7 51.9 26.4 24.2 30.1g

Ages 45-54 21.3 19.7 27.5 20.5 18.9 26.7 17.3 15.1 23.6Ages 55-64 21.9 21.2 24.7 21.4 21.0 23.1 17.6 15.8 24.2Ages 65-74 18.5 17.9 19.8 16.7 16.3 17.4 17.1 17.2 16.9Ages 75+ 9.8 9.7 10.0 8.1 8.0 8.2 8.5 7.1 9.5Ages <65 23.0 21.7 27.7 22.7 21.6 27.0 18.1 16.1 24.7Ages 65+ 14.9 14.9 14.7 13.1 13.3 12.6 14.8 15.1 14.0


Table 14.8Cancer of the Liver and Intrahepatic Bile Duct (Invasive)



SEE

R C


1975-2017N










2016 21.7 18.1 25.7 21.8 18.1 25.7 19.5 16.2 23.2






Table 15.12Cancer of the Lung and Bronchus (Invasive)



SEE

R C


1975-2017N


Note: Small Cell Cancer of the Lung and Bronchus includes histologies 8002, 8041-8045.a SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2017. Expected survival rates are derived from the U.S. Annual Life Tables.b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey,



d Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.e The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).f The standard error is between 5 and 10 percentage points.g The standard error is greater than 10 percentage points.- Statistic could not be calculated due to fewer than 25 cases during the time period.


5-Year Relative Survival (Percent)Year of Diagnosis:1975-1977a 3.6 3.1 4.8 3.7 3.1 4.9 3.7 3.8 3.61978-1980a 4.2 3.2 6.5 4.3 3.3 6.4 3.1 2.4 5.01981-1983a 4.5 3.5 6.2 4.6 3.6 6.1 5.3 4.1 8.21984-1986a 4.5 3.5 6.2 4.7 3.6 6.4 3.5 2.2 5.61987-1989a 5.0 3.9 6.6 5.1 3.8 6.8 4.0 3.3 5.11990-1992a 5.4 4.5 6.4 5.4 4.5 6.5 4.2 3.9 4.41993-1995a 6.4 5.1 7.8 6.2 5.0 7.6 6.7 4.0 10.41996-1998a 5.8 5.3 6.5 6.0 5.5 6.6 3.6 2.6 4.51999-2001a 5.7 4.8 6.7 5.6 4.4 6.9 5.2 6.0 4.22002-2004a 6.5 4.7 8.2 6.5 4.4 8.5 5.3 5.3 5.12005-2009a 6.8 5.2 8.5 6.7 5.1 8.4 6.7 4.5 8.92010-2016a 7.0e 5.7e 8.2e 7.0e 5.7e 8.2e 7.5e 7.1e 7.8

5-Year Period Survival (Percent)bc

2016 6.7 5.0 8.4 6.7 4.9 8.4 7.7 7.0 8.5

Stage Distribution (%) 2010-2016bd


5-Year Relative Survival (Percent), 2010-2016b

Age at Diagnosis:Ages <45 13.3 9.6 17.2 14.0 10.9 17.3 10.6 - -Ages 45-54 9.7 7.0 12.1 9.4 6.4 12.0 12.1 11.6 12.8Ages 55-64 7.8 5.7 10.0 7.8 5.6 10.0 8.0 5.9 10.1Ages 65-74 6.2 5.5 7.0 6.2 5.3 7.1 7.1 7.9 6.2Ages 75+ 3.7 2.8 4.5 3.7 2.7 4.5 3.5 2.1 4.5Ages <65 8.4 6.1 10.7 8.3 5.9 10.7 9.2 7.5 10.9Ages 65+ 5.2 4.5 6.0 5.2 4.3 6.0 5.8 6.1 5.5

Staged:All Stages 6.5 5.1 7.9 6.5 5.0 7.9 7.5 6.8 8.2Localized 27.2 25.5 28.3 27.2 25.4 28.4 34.9f 37.4f 32.1f

Regional 16.4 14.8 17.7 16.5 14.7 18.0 17.5 16.1 18.7Distant 2.9 2.0 3.8 2.8 1.9 3.7 3.8 3.3 4.2Unstaged/Unknown 8.1 5.7 10.2 8.0 4.2 11.0 3.4 6.6f -

Table 15.13Small Cell Cancer of the Lung and Bronchus (Invasive)



SEE

R C


1975-2017N


Note: Non-Small Cell Cancer of the Lung and Bronchus includes histologies 8003-8004, 8012-8015, 8021-8022, 8030-8035, 8046, 8050-8052,8070-8076, 8078, 8082-8084, 8090, 8094, 8120, 8123, 8140-8141, 8143-8145, 8147, 8190, 8200-8201, 8211, 8240-8241, 8243-8246,8249-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8430,8440,8470-8471,8480-8481, 8490, 8503, 8507, 8525, 8550, 8560, 8562,8570-8572, 8574-8576.




d Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.e The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).f The standard error is between 5 and 10 percentage points.g The standard error is greater than 10 percentage points.- Statistic could not be calculated due to fewer than 25 cases during the time period.


5-Year Relative Survival (Percent)Year of Diagnosis:1975-1977a 16.4 14.8 21.1 16.7 15.0 21.5 13.4 12.4 17.71978-1980a 16.7 14.8 21.4 17.0 15.2 21.5 14.2 11.6 22.81981-1983a 17.1 15.0 21.7 17.5 15.4 22.1 13.9 12.2 19.21984-1986a 16.6 14.4 21.0 17.0 14.7 21.5 13.1 11.9 16.41987-1989a 16.8 15.2 19.8 17.3 15.5 20.5 13.2 12.9 13.91990-1992a 17.7 15.5 21.1 18.3 16.2 21.7 12.8 11.1 16.21993-1995a 18.7 16.1 22.5 19.3 16.5 23.3 15.1 13.3 18.51996-1998a 19.4 16.7 22.9 19.9 17.1 23.5 15.3 12.7 19.51999-2001a 20.0 16.9 24.1 20.7 17.5 24.7 14.8 12.0 18.92002-2004a 19.6 17.0 22.8 20.4 17.7 23.7 15.0 13.9 16.62005-2009a 22.2 18.9 26.0 23.1 19.7 26.8 17.4 14.8 20.62010-2016a 26.5e 22.1e 31.2e 27.0e 22.5e 31.8e 23.4e 19.0e 28.1e


Stage Distribution (%) 2010-2016bdAll StagesNumber of cases 199,070 104,884 94,186 157,707 82,267 75,440 24,448 13,379 11,069Percent 100% 100% 100% 100% 100% 100% 100% 100% 100%Localized 20 17 23 21 18 24 16 14 18Regional 24 24 23 24 25 24 24 23 24Distant 54 57 52 53 55 51 59 62 56Unstaged/Unknown 2 2 2 2 2 2 2 2 2

5-Year Relative Survival (Percent), 2010-2016bAge at Diagnosis:Ages <45 38.7 33.3 43.7 40.6 35.0 45.6 30.1 26.1 34.8Ages 45-54 26.4 20.8 32.3 27.0 21.2 33.0 23.0 17.5 28.7Ages 55-64 25.7 21.2 31.4 26.0 21.6 31.6 22.1 18.2 27.8Ages 65-74 26.7 22.2 31.7 27.2 22.7 32.2 21.6 17.5 26.7Ages 75+ 20.8 17.0 24.5 21.3 17.4 24.9 15.8 11.7 19.7Ages <65 26.5 21.6 32.4 27.0 22.0 32.8 22.7 18.4 28.4Ages 65+ 24.0 19.9 28.3 24.4 20.3 28.7 19.4 15.4 23.8

Staged:All Stages 24.9 20.6 29.7 25.3 21.0 30.1 21.1 17.0 26.0Localized 63.1 56.7 68.4 63.2 57.0 68.4 58.1 49.1 65.9Regional 35.4 30.9 40.6 35.2 30.8 40.1 33.3 29.1 38.0Distant 6.9 5.6 8.6 6.6 5.2 8.2 6.6 5.6 8.0Unstaged/Unknown 14.8 14.2 15.5 13.7 12.9 14.6 11.5 9.4 13.5

Table 15.14Non-Small Cell Cancer of the Lung and Bronchus (Invasive)



SEE

R C


1975-2017N








5-Year Relative Survival (Percent)Year of Diagnosis:1960-1963a - - - 60 51 68 - - -1970-1973a - - - 68 62 75 - - -1975-1977b 81.9 77.5 86.3 82.1 77.9 86.3 56.7g - -1978-1980b 82.7 77.7 87.8 82.9 77.8 87.9 59.8h - -1981-1983b 82.8 78.4 87.3 82.8 78.5 87.2 61.9g - -1984-1986b 86.6 82.6 91.0 86.5 82.3 91.0 72.3h - -1987-1989b 88.1 84.9 91.5 88.0 84.9 91.3 78.6g - 89.5g

1990-1992b 89.3 87.0 91.8 89.4 87.2 91.8 59.7g - -1993-1995b 89.7 87.3 92.6 89.6 87.2 92.7 69.5g 66.6g -1996-1998b 91.0 89.5 92.7 90.9 89.4 92.7 73.9g 68.0h 78.6g

1999-2001b 92.2 90.2 94.6 92.3 90.3 94.6 73.9g 70.9g 76.1g

2002-2004b 93.2 91.1 95.5 93.2 91.1 95.7 72.2g - 70.9g

2005-2009b 93.3 91.7 95.3 93.4 91.8 95.4 73.0 61.1g 80.2g

2010-2016b 95.0f 93.4f 96.8f 94.9f 93.3f 96.9f 69.5g 65.2g 72.1g


2016 93.3 91.8 95.3 92.7 91.0 94.9 76.2 67.5 82.9


All StagesNumber of cases 108,462 61,289 47,173 100,723 57,211 43,512 485 212 273Percent 100% 100% 100% 100% 100% 100% 100% 100% 100%Localized 83 81 85 83 81 85 54 50 58Regional 9 10 7 9 10 8 25 29 22Distant 4 5 3 4 5 3 16 16 15Unstaged/Unknown 4 4 4 4 4 4 5 6 4


Age at Diagnosis:Ages <45 95.1 92.2 97.0 94.9 91.9 96.9 87.2 81.9g 89.2g

Ages 45-54 93.7 91.4 96.3 93.5 91.0 96.2 58.8g 43.7h 72.9g

Ages 55-64 92.8 91.2 95.3 92.4 90.8 95.0 69.8 59.3g 80.8g

Ages 65-74 93.4 92.5 95.1 92.9 91.9 94.8 68.6g 64.3g 71.2g

Ages 75+ 87.9 87.7 88.3 86.7 86.2 87.5 33.3h 34.1h 30.0h

Ages <65 93.8 91.5 96.2 93.5 91.1 96.1 72.9 60.0g 82.6Ages 65+ 91.1 90.6 91.9 90.2 89.5 91.4 55.9g 55.8g 54.5g

Stagee:All Stages 92.7 91.1 94.8 92.2 90.4 94.5 66.7 59.5 72.1Localized 99.0 98.7 99.4 98.6 98.1 99.2 85.2 82.4g 86.6Regional 66.2 63.5 70.7 66.5 63.8 71.1 49.4g 44.9g 53.3g

Distant 27.3 26.2 29.7 27.3 26.3 29.6 26.7g - 35.8g

Unstaged/Unknown 87.2 85.6 88.8 85.4 83.6 87.3 - - -

Table 16.8Melanoma of the Skin (Invasive)



SEE

R C


1975-2017N








5-Year Relative Survival (Percent)Year of Diagnosis:1960-1963a - - - - - - - - -1970-1973a - - - - - - - - -1975-1977b 9.7 3.0 26.7 10.4 3.3 27.4f - - -1978-1980b 6.0 5.5 8.1 5.9 5.2 8.7 - - -1981-1983b 7.7 5.3 15.1 8.1 5.4 16.2 - - -1984-1986b 6.6 4.3 13.9 6.1 3.7 14.1 - - -1987-1989b 6.3 4.6 12.2 6.4 4.8 12.1 4.8 - -1990-1992b 7.7 4.2 20.6 7.4 4.0 20.1 10.2f 8.5f -1993-1995b 6.5 3.2 18.7 5.9 2.8 18.0 9.0 8.0f -1996-1998b 9.8 8.2 15.2 9.8 8.0 16.2 11.4f - -1999-2001b 7.6 5.3 15.9 6.7 5.0 13.0 - - -2002-2004b 6.6 4.9 11.6 6.1 4.5 10.9 7.9f - -2005-2009b 10.1 7.3 18.4 10.6 7.4 20.7 6.7 5.6f -2010-2016b 10.7 8.3e 18.6 10.1 7.9e 17.4 13.7f 0.0 -


2016 12.2 9.2 20.8 11.6 8.6 20.6 17.3 16.2 18.5


Age at Diagnosis:Ages <45 42.2f 31.8f 52.8f 42.7f 33.1f 53.5f - - -Ages 45-54 23.3 17.6 31.8f 21.1 16.2 29.0f 32.0f - -Ages 55-64 14.3 12.7 18.3 13.6 12.1 17.6 18.1f 14.6f -Ages 65-74 8.9 6.9 16.2 8.8 6.8 16.2 9.1 9.7 -Ages 75+ 4.6 3.9 7.0 4.3 3.4 7.3 4.3 3.0 -Ages <65 19.9 15.6 28.0 18.8 15.0 26.3 25.4f 15.7f 34.2f

Ages 65+ 6.4 5.2 10.8 6.2 4.9 10.9 7.0 6.6 -

Table 17.4Mesothelioma



SEE

R C


1975-2017N








5-Year Relative Survival (Percent)Year of Diagnosis:1960-1963a - - - 12 13 10 - - -1970-1973a - - - 19 20 17 - - -1975-1977b 24.5 23.9 25.2 24.0 23.6 24.6 29.3 28.9 29.51978-1980b 25.9 24.4 27.4 24.8 24.1 25.4 32.5 27.4 37.51981-1983b 27.6 25.8 29.5 27.3 25.6 29.1 28.9 29.6 27.91984-1986b 27.3 27.7 26.9 26.1 25.9 26.3 31.8 33.3 30.31987-1989b 27.2 28.9 25.4 26.8 29.1 24.4 29.9 29.6 30.11990-1992b 29.3 30.5 27.9 28.4 29.6 26.9 34.4 38.0 30.91993-1995b 31.7 32.3 31.0 30.6 31.5 29.5 35.4 34.9 35.71996-1998b 32.5 34.5 30.3 32.2 34.4 29.8 31.7 33.2 30.61999-2001b 34.6 37.2 31.6 34.5 37.2 31.3 34.3 37.2 31.72002-2004b 42.6 43.6 41.5 43.4 44.8 41.7 41.1 41.6 40.72005-2009b 48.9 49.3 48.4 48.3 49.8 46.5 51.1 47.6 54.22010-2016b 55.1f 55.9f 54.2f 54.5f 55.5f 53.1f 56.8f 57.1f 56.6f


2016 55.1 55.4 54.8 53.7 54.1 53.2 57.9 57.9 57.9





Stagee:All Stages 53.9 53.7 54.1 52.7 52.8 52.5 56.8 56.3 57.3Localized 74.8 76.2 72.6 75.8 77.3 73.1 67.8 69.3g 66.0g

Regional - - - - - - - - -Distant 52.9 52.5 53.3 51.4 51.3 51.5 56.4 55.8 57.0Unstaged/Unknown - - - - - - - - -

Table 18.8Myeloma



SEE

R C


1975-2017N








5-Year Relative Survival (Percent)Year of Diagnosis:1960-1963a - - - 31 31 31 - - -1970-1973a - - - 41 39 43 - - -1975-1977b 46.5 45.5 47.5 46.8 46.3 47.3 48.6 42.6 55.3g

1978-1980b 47.9 46.1 49.8 47.9 46.3 49.6 51.1 46.9 56.71981-1983b 50.6 50.3 50.9 50.7 50.5 51.0 49.5 49.2 49.81984-1986b 51.6 50.0 53.3 52.0 50.6 53.6 46.8 44.5 49.91987-1989b 50.9 47.6 54.9 51.4 48.2 55.2 45.7 41.3 51.01990-1992b 50.7 46.7 55.7 51.5 47.6 56.4 42.2 38.4 47.61993-1995b 52.6 48.8 57.5 53.3 49.8 57.7 42.6 35.9 55.11996-1998b 58.8 57.0 61.0 59.4 57.6 61.5 54.8 53.2 57.31999-2001b 64.0 61.5 67.0 65.0 62.9 67.5 55.7 49.1 63.72002-2004b 69.8 68.6 71.2 71.0 70.1 72.1 63.7 61.3 66.62005-2009b 72.1 71.0 73.4 73.3 72.4 74.5 62.9 58.3 68.02010-2016b 75.1f 74.3f 76.1f 75.9f 75.1f 76.9f 71.5f 69.0f 74.4f


2016 73.1 71.9 74.5 73.5 72.2 75.1 69.2 67.6 70.8






Table 19.8Non-Hodgkin Lymphoma



SEE

R C


1975-2017N








5-Year Relative Survival (Percent)Year of Diagnosis:1960-1963a - - - 45 - - - - -1970-1973a - - - 43 - - - - -1975-1977b 52.5 51.5 54.7 54.0 53.7 54.7 36.0 29.7 49.01978-1980b 53.3 51.8 56.5 55.4 54.5 57.4 34.9 29.8 45.81981-1983b 51.7 50.1 55.1 54.0 52.9 56.5 30.9 25.4 45.61984-1986b 54.1 51.6 59.0 56.3 54.8 59.4 35.0 29.5 49.11987-1989b 53.6 51.1 58.8 56.0 54.1 59.8 34.0 30.0 44.01990-1992b 55.4 53.1 60.1 57.9 56.4 61.0 33.1 28.4 46.01993-1995b 57.6 56.2 60.5 60.0 59.4 61.3 38.0 33.1 50.51996-1998b 57.8 56.2 61.0 59.9 59.1 61.5 36.3 31.3 49.21999-2001b 60.3 59.2 62.6 62.3 62.1 62.7 44.6 39.4 57.32002-2004b 63.9 63.1 65.8 65.7 65.7 65.7 48.4 43.1 58.82005-2009b 65.9 65.4 67.2 67.7 67.5 68.2 44.8 42.2 50.42010-2016b 69.2f 68.5f 71.1f 71.2f 70.9f 72.2f 51.3f 49.6f 54.9


2016 66.5 66.2 67.2 67.6 67.6 67.7 50.1 49.7 50.6






Table 20.10Cancer of the Oral Cavity and Pharynx (Invasive)



SEE

R C


1975-2017N


Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.a Based on End Results data from a series of hospital registries and one population-based registry.b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).






5-Year Relative Survival (Percent)Year of Diagnosis:1960-1963a - - - 32 - - 32 - -1970-1973a - - - 36 - - 32 - -1975-1977b 35.9 44.1 21.3 35.2 43.5 21.0 41.6 48.6 24.9g1978-1980b 37.6 47.3 21.9 36.8 46.4 22.1 38.8 49.2 12.81981-1983b 38.9 50.3 23.1 38.5 50.2 23.1 37.9 46.0 22.61984-1986b 38.5 49.4 24.2 37.6 48.5 23.9 39.2 51.9 21.21987-1989b 38.2 51.1 23.6 38.2 51.3 23.9 33.9 47.2 17.11990-1992b 40.6 55.6 24.1 40.5 56.2 24.1 35.7 49.4 16.81993-1995b 41.6 55.9 26.6 40.7 55.5 26.1 41.3 54.8 26.41996-1998b 43.8 57.1 28.2 43.2 56.5 28.4 39.2 53.3 20.41999-2001b 43.9 56.0 28.9 43.6 56.6 28.8 35.7 44.2 21.92002-2004b 43.9 57.0 27.0 43.3 56.8 27.2 36.9 46.8 20.82005-2009b 45.8 59.2 27.6 45.5 59.4 28.1 37.1 46.1 22.22010-2016b 49.4f 61.4f 32.8f 49.1f 62.1f 33.0f 42.2 52.1 24.2

5-Year Period Survival (Percent)cd2016 49.3 61.0 33.3 48.9 61.6 33.3 42.3 51.7 24.5

Stage Distribution (%) 2010-2016ceAll StagesNumber of cases 34,175 19,504 14,671 27,575 15,102 12,473 3,109 1,938 1,171Percent 100% 100% 100% 100% 100% 100% 100% 100% 100%Localized 16 22 8 15 21 8 15 20 7Regional 21 25 15 21 25 15 16 19 12Distant 58 50 68 59 50 68 63 57 72Unstaged/Unknown 5 3 8 5 3 8 6 5 9

5-Year Relative Survival (Percent), 2010-2016cAge at Diagnosis:Ages <45 77.1 - - 78.1 - - 72.6 - -Ages 45-54 61.1 - - 61.6 - - 51.8 - -Ages 55-64 51.4 - - 52.5 - - 38.3 - -Ages 65-74 41.1 - - 42.0 - - 26.0 - -Ages 75+ 23.2 - - 23.0 - - 17.7 - -Ages <65 60.5 - - 61.1 - - 51.3 - -Ages 65+ 32.4 - - 32.7 - - 22.2 - -

Stagee:All Stages 48.6 60.5 32.4 48.4 61.1 32.7 40.8 51.3 22.2Localized 92.6 93.9 87.9 93.3 94.8 88.1 89.5 91.2 80.1gRegional 74.8 80.8 61.6 75.5 82.0 62.5 64.3 71.3 43.1gDistant 30.2 37.9 22.6 30.4 38.6 22.7 23.6 29.7 15.1Unstaged/Unknown 25.5 52.4 10.5 23.4 51.1 10.2 30.7 57.2g 6.5

Table 21.8Cancer of the Ovary(Invasive)



SEE

R C


1975-2017N










2016 11.0 11.0 11.0 10.8 10.9 10.7 10.6 9.8 11.2






Table 22.8Cancer of the Pancreas (Invasive)



SEE

R C


1975-2017N







All Races, Males White Males Black Males All <65 65+ All <65 65+ All <65 65+

5-Year Relative Survival (Percent)Year of Diagnosis:1960-1963a - - - 50 - - 35 - -1970-1973a - - - 63 - - 55 - -1975-1977b 67.8 73.4 66.1 68.5 75.2 66.6 60.7 62.0 60.11978-1980b 70.1 75.2 68.6 71.2 76.7 69.6 62.1 65.0 60.61981-1983b 72.0 76.0 70.9 73.1 77.6 71.9 62.8 65.0 61.91984-1986b 75.1 77.2 74.5 76.3 78.9 75.6 65.6 67.2 64.91987-1989b 82.8 83.2 82.7 84.4 84.7 84.3 71.2 72.8 70.71990-1992b 92.9 92.9 92.9 94.1 94.0 94.1 84.5 86.8 83.61993-1995b 95.2 95.9 94.9 96.0 96.5 95.7 91.9 93.4 91.01996-1998b 97.3 98.5 96.7 97.9 98.9 97.3 95.0 96.7 93.71999-2001b 99.3 99.1 99.3 99.7 99.5 99.6 97.4 98.1 96.42002-2004b 99.6 99.5 99.7 99.8 99.6 99.7 98.0 99.2 96.32005-2009b 99.5 99.6 99.4 99.8 99.9 99.6 98.3 98.6 97.82010-2016b 98.3f 99.0f 97.7f 98.7f 99.4f 98.1f 96.3f 97.5f 94.4f


2016 97.3 97.9 96.8 97.2 98.0 96.6 95.9 97.2 94.2






Table 23.8Cancer of the Prostate (Invasive)



SEE

R C


1975-2017N










2016 32.2 29.1 36.9 30.8 27.5 36.3 32.6 27.5 39.3






Table 24.8Cancer of the Stomach (Invasive)



SEE

R C


1975-2017N







All Races, Males White Males Black Males All <50 50+ All <50 50+ All <50 50+

5-Year Relative Survival (Percent)Year of Diagnosis:1960-1963a - - - 63 - - - - -1970-1973a - - - 72 - - - - -1975-1977b 82.7 83.3 77.7 82.6 83.3 77.4 - - -1978-1980b 88.8 89.5 82.2 89.2 89.8 83.1 73.1g 78.0g -1981-1983b 92.0 92.5 85.5 92.2 92.8 86.2 87.7g 84.7g -1984-1986b 92.6 93.6 80.4 92.9 94.0 80.6 87.0g 89.4g -1987-1989b 95.2 95.0 95.7 95.5 95.4 95.3 88.0g 87.4g -1990-1992b 95.8 95.8 93.7 96.2 96.1 94.6 84.2g 89.0g -1993-1995b 95.8 96.4 86.7 96.1 96.6 87.8 88.0 89.4 -1996-1998b 95.6 96.3 86.6 95.8 96.5 86.7 89.0 90.3 -1999-2001b 96.1 96.4 91.8 96.4 96.7 92.8 87.6 89.1 -2002-2004b 96.0 96.5 89.9 96.5 97.0 90.9 85.1 84.8g -2005-2009b 96.9 97.0 95.7 97.4 97.4 96.4 91.4 91.4 -2010-2016b 96.8f 97.1f 94.6f 97.0f 97.3f 95.0f 93.1 93.0 89.5g


2016 95.1 95.9 89.2 95.1 96.0 89.5 93.2 93.9 84.6


All StagesNumber of cases 16,682 14,675 2,007 14,758 12,954 1,804 540 458 82Percent 100% 100% 100% 100% 100% 100% 100% 100% 100%Localized 68 68 65 68 68 64 63 61 70Regional 18 18 19 19 18 19 20 21 15Distant 12 12 14 12 12 14 14 15 12Unstaged/Unknown 2 1 3 1 1 3 3 2 4


Age at Diagnosis:Ages <45 95.6 - - 95.6 - - 91.9 - -Ages 45-54 95.1 - - 95.2 - - 90.3 - -Ages 55-64 90.1 - - 89.9 - - 93.9 - -Ages 65-74 84.8 - - 83.1 - - - - -Ages 75+ 74.7g - - 77.2h - - - - -Ages <65 95.3 - - 95.3 - - 92.4 - -Ages 65+ 82.8 - - 82.1 - - - - -

Stagee:All Stages 95.0 95.6 90.6 95.0 95.7 90.4 92.3 92.5 88.4Localized 99.0 99.1 98.4 99.0 99.1 98.0 98.8 97.9 97.1Regional 96.0 96.6 91.3 96.2 96.8 92.0 88.6 89.9 -Distant 72.5 75.0 57.0 73.0 75.5 57.7 68.9g 71.5g -Unstaged/Unknown 81.6 89.0 55.6g 79.3 87.5 55.2h - - -

Table 25.8Cancer of the Testis (Invasive)



SEE

R C


1975-2017N








5-Year Relative Survival (Percent)Year of Diagnosis:1960-1963a - - - 83 75 87 - - -1970-1973a - - - 86 82 87 - - -1975-1977b 92.2 91.0 92.5 91.8 90.6 92.3 89.8 - 91.01978-1980b 92.1 87.2 93.6 91.5 87.5 92.7 90.1 68.0h 95.51981-1983b 93.6 92.2 93.9 93.1 90.9 93.7 96.4 100.0 93.21984-1986b 93.2 89.9 94.3 93.2 89.4 94.4 89.5 86.1g 90.31987-1989b 94.4 91.6 95.2 94.1 91.6 95.0 92.3 91.2g 92.31990-1992b 94.3 90.5 95.5 94.9 91.6 96.0 85.9 84.5g 86.31993-1995b 95.4 91.6 96.7 95.6 91.5 96.9 93.2 87.4g 94.31996-1998b 95.6 91.0 96.9 95.9 91.3 97.3 95.1 86.8g 96.51999-2001b 96.5 94.2 97.1 96.8 94.8 97.4 92.1 88.4g 92.42002-2004b 97.3 93.9 98.3 97.4 94.1 98.3 95.9 93.9 96.02005-2009b 98.2 96.4 98.6 98.4 96.8 98.8 97.0 90.2 97.92010-2016b 98.6f 96.2f 99.0f 98.8f 96.7f 99.3f 96.7 91.6 97.5f


2016 98.4 96.2 99.0 98.6 96.4 99.1 97.0 93.4 97.6


All StagesNumber of cases 78,663 18,363 60,300 62,568 15,130 47,438 5,628 971 4,657Percent 100% 100% 100% 100% 100% 100% 100% 100% 100%Localized 67 57 69 67 57 70 79 72 81Regional 28 34 26 28 35 26 14 18 13Distant 4 6 3 3 6 3 5 7 4Unstaged/Unknown 2 2 2 2 2 2 2 3 2


Age at Diagnosis:Ages <45 99.7 99.2 99.8 99.8 99.4 99.8 98.9 95.0 99.5Ages 45-54 98.9 96.7 99.5 98.9 96.7 99.5 99.0 96.6 99.2Ages 55-64 97.9 95.3 98.9 98.2 95.2 99.3 95.5 94.2 95.5Ages 65-74 96.7 93.0 97.7 97.1 93.8 97.9 94.6 82.5g 97.1Ages 75+ 87.3 86.0 87.7 89.5 87.9 89.8 79.6 76.1h 78.4Ages <65 99.1 97.3 99.6 99.1 97.3 99.7 98.3 95.5 98.8Ages 65+ 94.1 91.0 94.9 94.9 92.2 95.4 90.7 81.8 91.9

Stagee:All Stages 98.3 95.9 98.9 98.5 96.2 99.1 97.2 92.8 97.9Localized 99.9 99.8 99.9 99.9 99.8 99.9 99.8 99.3 99.9Regional 98.3 96.5 99.0 98.4 96.6 99.2 94.8 86.6 97.0Distant 54.9 51.7 57.2 55.1 51.1 58.3 48.2 40.2g 49.8Unstaged/Unknown 88.5 80.6 91.0 88.4 82.4 90.5 82.7 70.3h 85.5

Table 26.8Cancer of the Thyroid (Invasive)



SEE

R C


1975-2017N









1978-1980b 73.9 75.0 70.4 74.7 75.4 72.4 54.7 62.8 40.01981-1983b 76.7 78.0 72.8 77.3 78.5 74.1 59.5 64.9 47.0g

1984-1986b 76.6 78.0 72.7 77.2 78.4 73.6 59.4 62.3 52.81987-1989b 79.0 81.3 72.0 79.8 82.0 73.2 62.6 67.5 52.91990-1992b 79.2 81.7 71.9 80.3 82.6 73.2 63.3 66.0 58.51993-1995b 80.2 82.1 75.0 81.1 82.5 76.9 60.7 68.0 46.21996-1998b 79.1 80.3 75.4 79.8 81.1 76.0 62.9 65.9 56.01999-2001b 80.0 80.9 77.2 81.0 81.5 79.4 67.5 71.8 60.12002-2004b 79.9 81.7 74.7 80.9 82.4 76.4 61.7 67.1 52.42005-2009b 79.1 80.5 74.9 79.9 81.1 76.1 65.8 70.0 57.62010-2016b 78.1f 79.0f 75.3f 79.0f 79.5f 77.0f 64.9f 69.1f 56.8f


2016 76.9 78.2 72.8 77.3 78.4 73.8 64.1 68.4 56.1


All StagesNumber of cases 91,766 69,653 22,113 80,385 61,596 18,789 5,331 3,507 1,824Percent 100% 100% 100% 100% 100% 100% 100% 100% 100%In Situ 51 52 50 52 52 51 40 44 33Localized 34 34 32 34 34 32 36 36 38Regional 7 7 8 7 7 8 11 9 13Distant 5 4 6 5 4 6 9 7 11Unstaged/Unknown 3 3 3 3 2 3 4 4 4


Age at Diagnosis:Ages <45 86.9 88.7 82.4 88.1 89.4 84.8 69.0 73.7 57.4g

Ages 45-54 83.8 84.5 81.6 85.0 85.4 83.8 68.7 72.6 58.8Ages 55-64 81.2 81.6 80.0 81.9 81.9 82.0 66.8 70.1 58.0Ages 65-74 80.3 81.1 77.5 80.4 81.1 77.8 67.7 70.3 62.0Ages 75+ 68.9 71.2 62.7 69.5 71.5 63.8 54.6 60.3 47.7Ages <65 82.3 82.8 80.6 83.1 83.2 82.7 67.5 71.1 58.2Ages 65+ 74.2 76.0 68.7 74.6 76.2 69.5 61.1 65.9 53.4

Stagee:All Stages 76.9 78.3 72.4 77.3 78.5 73.5 63.9 68.4 55.2In Situ 95.8 95.5 97.0 95.8 95.4 97.0 92.5 92.1 93.5Localized 69.2 71.7 61.2 69.4 71.6 61.7 60.4 65.7 50.7Regional 36.5 38.0 32.8 37.6 39.0 33.5 27.3 26.1 28.0Distant 5.5 6.2 4.0 5.5 6.1 4.3 3.4 4.8 1.7Unstaged/Unknown 47.9 52.3 36.6 46.0 49.7 36.2 39.3 46.3g 25.1g

Table 27.8Cancer of the Urinary Bladder (Invasive and In Situ)



Figure 29.3

Childhood Cancer5-Year Observed Survival (%)

by ICCC Group and Race/EthnicityBoth Sexes, Under 20 Years of Age, 2010-2016

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).International Classification of Childhood Cancer is based on ICD-O-3. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, Third Edition. Cancer. April 1, 2005: Vol 103, No. 7,pg 1457-1467.Excludes myelodysplastic sydromes (MDS) and benign brain tumors.American Indian/Alaska Native. Survival data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/AlaskaNatives. Survival data for Hispanics are based on NHIA and excludes cases from the Alaska Native Registry.

0

20

40

60

80

100

LymphoidLeukemias

Other Leukemia Lymphoma Brain/CNS Other

White Black AI/AN

Asian/Pacific Islander Hispanic

5-Year Observed Survival

ICCC Site

c

b

a

a

b

c


Documents

SEER Cancer Statistics Review 1975-2017 National Cancer Institute · 2020-04-10 · SEER Cancer Statistics Review 1975-2017 National Cancer Institute Note: Incidence and death rates